Search

Actinogen buys Corticrine, pursues dementia treatment

Biotech firm Actinogen has signed an agreement to buy pharmaceutical company Corticrine for about $5.75 million, which focuses on the development of treatments for disease modification and prevention in Alzheimer’s dementia.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Actinogen (ACW)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Share Transactions

24/12/15
$630 Bought
20/05/15
$15k Issued
01/12/14
$40k Bought
Total value as at the date of the transaction
Source: Morningstar

BNiQ Disclaimer